SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

   Biotech / MedicalClosure Medical (CLSR) fomerly Tri-Point Medical (TPMC)


Previous 10 
To: Bill Holtzman who wrote (176)3/1/1999 10:15:00 PM
From: Ben Wa
   of 184
 
Every medical device that is on ER, or better yet...General Hospital - invest in those companies. It'll be a sure fire strategy.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Ben Wa who wrote (177)8/9/1999 10:15:00 AM
From: Marty Rubin
   of 184
 
I would like to get into this company. any advice? this is a 'safe' stock if the economy slows. oversupply may drown over the course of the summer, though with the heat wave, less activity may mean less injuries. stock's +/- $15.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Marty Rubin who wrote (178)8/12/1999 1:09:00 PM
From: Marty Rubin
   of 184
 
50.8K was bought @ 15 3/16 a few minutes ago. Total vol now 77K eom-)

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Marty Rubin who wrote (179)9/7/1999 6:12:00 PM
From: Marty Rubin
   of 184
 
"Closure Medical Corporation Announces FDA Approval of Soothe-N-Seal(TM) Canker Sore Relief"

Tuesday September 7, 11:16 am Eastern Time
Company Press Release


SOURCE: CLOSURE Medical Corporation

Closure Medical Corporation Announces FDA Approval of Soothe-N-Seal(TM) Canker Sore Relief

RALEIGH, N.C., Sept. 7 /PRNewswire/ -- CLOSURE Medical Corporation (Nasdaq: CLSR - news), a medical tissue cohesive products company, today announced it has received FDA clearance to market its SOOTHE-N-SEAL(TM) Canker Sore Relief product.

''SOOTHE-N-SEAL(TM) is the first cyanoacrylate adhesive approved by the FDA for the over-the-counter consumer market. Based upon primary market research, we believe that there are about 40 million households within the U.S. alone in which one or more members have suffered from oral ulcers within the past 6 months,'' said Mr. Robert V. Toni, President and CEO of CLOSURE Medical Corporation.

The approval is based in part on the findings of a sponsored 155-patient multi-center clinical study conducted at Brigham & Women's Hospital, UNC-Chapel Hill, and the Forsyth Institute. In the multi-center study, SOOTHE-N-SEAL(TM) Canker Sore Relief was found to provide relief of pain associated with oral ulcers. In addition, SOOTHE-N-SEAL(TM) provided a protective barrier that reduced the pain associated with irritation from eating and drinking.

CLOSURE Medical Corporation is currently in discussions for a marketing distribution agreement for SOOTHE-N-SEAL(TM) Canker Sore Relief. CLOSURE believes SOOTHE-N-SEAL(TM) is the first of a number of OTC consumer products utilizing its proprietary cyanoacrylate technology.

CLOSURE Medical Corporation, headquartered in Raleigh, North Carolina, develops, manufactures and commercializes medical tissue cohesive products based on its proprietary cyanoacrylate technology. CLOSURE's nonabsorbable tissue cohesive products may be used to replace sutures and staples for certain topical wound closure applications, while its absorbable tissue cohesive products can potentially be used as tissue cohesives for internal wound closure and management. Currently marketed nonabsorbable tissue cohesive products include DERMABOND* Topical Skin Adhesive, which is used to replace sutures and staples for closure of certain lacerations and incisions, OCTYLDENT® cohesive, which is used as an adjunct in the treatment of adult periodontal disease; and NEXABAND® topical cohesives, a family of products used in veterinary wound closure and management.

DERMABOND is a trademark of Ethicon, Inc.; SOOTHE-N-SEAL, OCTYLDENT and NEXABAND are all trademarks of CLOSURE Medical Corporation.
To receive CLOSURE's latest news release and other corporate documents via fax, at no cost, call 1-800-PRO-INFO. Use the Company's ticker, CLSR. Or visit the Financial Relations Board's website at www.frbinc.com .

This release contains certain forward-looking statements which involve known and unknown risks, delays, uncertainties or other factors not under the Company's control which may cause actual results, performance or achievements of the Company to be materially different from the results, performance, or other expectations implied by these forward-looking statements. These factors include, but are not limited to the early stage of commercialization of the Company products; the progress of its research and development programs for future nonabsorbable and over-the-counter products; the need for regulatory approval and effects of governmental regulation; technological uncertainties; dependence on marketing partners, and dependence on patents and trade secrets, as well as those detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 1998 filed with the Securities and Exchange Commission.

SOURCE: CLOSURE Medical Corporation

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Marty Rubin who wrote (180)7/25/2000 3:57:27 PM
From: Sr K
   of 184
 
Apparently there is no support. Tanking in anticipation of the "earnings" report.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Sr K who wrote (181)12/6/2000 12:27:18 AM
From: Toby Zidle
   of 184
 
This "tanked" stock is now above $32, trading more than 3x normal volume today.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Toby Zidle who wrote (182)1/14/2001 11:21:31 PM
From: Ron
   of 184
 
CLSR looks way oversold here to me. Bought some on Friday's tank. Their prospects are better than ever!

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Ron who wrote (183)1/15/2001 11:57:49 PM
From: Toby Zidle
   of 184
 
What a difference five weeks make! I held on and watched it dive, especially late in the day. I can't see a justification for that kind of reaction, even if Robbie Stephens did downgrade the stock.

There's an important lesson, however, in not fighting the tape. If CLSR stagnates in the $17-$19 area, I think it becomes best to take one's loss and move on.

I'll be patient for the next three days or so (unless it falls under $16 = SELL), but if we get no recovery within that period, it'll be better to find a stock that is moving up. (NTBK was my last purchase on Friday.)

Share RecommendKeepReplyMark as Last Read
Previous 10